Biomea Fusion, Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 59.22. In total, the insiders bought 10 173 803 and sold 5 315 253 BMEA shares in the last 100 trades.

Insider Power

(Last 100 transactions)
59.22
Buy 10 173 803 Shares
Sell 5 315 253 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 12, 2024 Stock Option (right to buy) Buy Chen Bihua 51 025
Jun 12, 2024 Stock Option (Right to Buy) Buy Ray Sumita 51 025
Jun 12, 2024 Stock Option (Right to Buy) Buy Faust Elizabeth 51 025
Jun 12, 2024 Stock Option (Right to Buy) Buy Hitchcock Michael J.m. 51 025
Jun 12, 2024 Stock Option (Right to Buy) Buy Aguiar Eric 51 025
Jun 11, 2024 Common Stock Buy Valle Franco 12 509
May 31, 2024 Common Stock Buy Valle Franco 4 448
May 31, 2024 Common Stock Buy Frias Juan Pablo 349
Jan 17, 2024 Stock Option (Right to Buy) Buy Butler Thomas Andrew 407 502
Jan 17, 2024 Stock Option (Right to Buy) Buy Erdtmann Rainer M 135 700
Jan 17, 2024 Stock Option (Right to Buy) Buy Valle Franco 145 245
Jan 17, 2024 Stock Option (Right to Buy) Buy Frias Juan Pablo 111 090
Dec 29, 2023 Common Stock Sell Erdtmann Rainer M 3 000
Dec 29, 2023 Common Stock Sell Erdtmann Rainer M 3 000
Dec 29, 2023 Common Stock Sell Erdtmann Rainer M 3 000
Dec 29, 2023 Common Stock Sell Erdtmann Rainer M 12 000
Dec 29, 2023 Common Stock Buy Erdtmann Rainer M 3 000
Dec 29, 2023 Common Stock Buy Erdtmann Rainer M 3 000
Nov 30, 2023 Common Stock Buy Valle Franco 1 345
Aug 31, 2023 Stock Option (Right to Buy) Buy Frias Juan Pablo 300 000
Aug 31, 2023 Buy Frias Juan Pablo 0
Jun 14, 2023 Stock Option (Right to Buy) Buy Hitchcock Michael J.m. 6 989
Jun 14, 2023 Stock Option (right to buy) Buy Chen Bihua 6 989
Jun 14, 2023 Stock Option (Right to Buy) Buy Faust Elizabeth 6 989
Jun 14, 2023 Stock Option (Right to Buy) Buy Ray Sumita 6 989
Click to get the best stock tips daily for free!

About Biomea Fusion, Inc.

Biomea Fusion. Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in R... BMEA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT